13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001633313
Total reported value
$11.1B
$11.1B
33 檔
31.7%
During the Q1 2025 filing period, Avoro Capital Advisors LLC (CIK: 0001633313) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $11.1B across 33 reported positions.
In Q1 2025, Avoro Capital Advisors LLC displayed an active expansion posture, initiating 33 new positions and adding to 0 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | UTHR | United Therapeutics CORP | Stock-Healthcare | 12.87% | -1.92% | -3.09% | |
| 2 | ASND | Ascendis Pharma A/S | Stock-Other | 12.69% | -11.39% | EXIT | |
| 3 | ARGX | Argenx Se - Adr | Stock-Healthcare | 11.41% | +1.15% | -0.27% | |
| 4 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 10.46% | -0.52% | -0.33% | |
| 5 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 7.69% | +2.30% | +3.89% | |
| 6 | 2655787D | Blueprint Medicines CORP | Stock-Other | 5.32% | — | +224.89% | |
| 7 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 4.17% | -4.84% | EXIT | |
| 8 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 3.51% | — | +1.67% | |
| 9 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 3.01% | -0.18% | +1.32% | |
| 10 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 2.82% | -0.76% | EXIT | |
| 11 | KYMR | Kymera Therapeutics Inc | Stock-Other | 2.76% | +1.58% | +25.44% | |
| 12 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 2.66% | — | +4.67% | |
| 13 | AM6 | Amicus Therapeutics Inc | Stock-Other | 2.61% | — | -11.54% | |
| 14 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 2.21% | +1.71% | — | |
| 15 | VERA | Vera Therapeutics Inc | Stock-Other | 2.14% | -0.12% | +1.64% | |
| 16 | ✓ | Merus N V | Stock-Other | 1.97% | — | +41.18% | |
| 17 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 1.69% | — | — | |
| 18 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 1.29% | — | -79.51% | |
| 19 | ALKS | Alkermes plc | Stock-Healthcare | 1.26% | -0.42% | EXIT | |
| 20 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 1.02% | — | -26.68% | |
| 21 | OCUL | Ocular Therapeutix Inc | Stock-Other | 0.92% | +0.08% | — | |
| 22 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.91% | -4.47% | EXIT | |
| 23 | ETNBGBP | 89bio Inc | Stock-Other | 0.72% | — | +54.88% | |
| 24 | MNKD | Mannkind CORP | Stock-Other | 0.69% | -0.05% | EXIT | |
| 25 | PCVX | Vaxcyte Inc | Stock-Other | 0.59% | — | -14.89% | |
| 26 | TRML | Tourmaline Bio Inc | Stock-Other | 0.58% | — | +9.13% | |
| 27 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.47% | — | — | |
| 28 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.43% | +0.51% | — | |
| 29 | QURE | uniQure N.V. | Stock-Other | 0.36% | +1.82% | — | |
| 30 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.34% | — | +6.92% | |
| 31 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.24% | — | — | |
| 32 | SEPN | Septerna Inc | Stock-Other | 0.12% | +0.08% | +20.50% | |
| 33 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 0.08% | +0.02% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | UTHR | United Therapeutics CORP | — | NEW | New buy |
| 2 | ASND | Ascendis Pharma A/S | — | NEW | New buy |
| 3 | ARGX | Argenx Se - Adr | — | NEW | New buy |
| 4 | MDGL | Madrigal Pharmaceuticals Inc | — | NEW | New buy |
| 5 | KRYS | Krystal Biotech Inc | — | NEW | New buy |
| 6 | 2655787D | Blueprint Medicines CORP | — | NEW | New buy |
| 7 | APLSUSD | Apellis Pharmaceuticals Inc | — | NEW | New buy |
| 8 | RNAGBP | Avidity Biosciences Inc | — | NEW | New buy |
| 9 | XENE | Xenon Pharmaceuticals Inc | — | NEW | New buy |
| 10 | SLNOEUR | Soleno Therapeutics Inc | — | NEW | New buy |
| 11 | KYMR | Kymera Therapeutics Inc | — | NEW | New buy |
| 12 | SRPT | Sarepta Therapeutics Inc | — | NEW | New buy |
| 13 | AM6 | Amicus Therapeutics Inc | — | NEW | New buy |
| 14 | ARWR | Arrowhead Pharmaceuticals In | — | NEW | New buy |
| 15 | VERA | Vera Therapeutics Inc | — | NEW | New buy |
| 16 | ✓ | Merus N V | — | NEW | New buy |
| 17 | MLTX | Moonlake Immunotherapeutics | — | NEW | New buy |
| 18 | ITCIEUR | Intra-cellular Therapies Inc | — | NEW | New buy |
| 19 | ALKS | Alkermes plc | — | NEW | New buy |
| 20 | BCRX | Biocryst Pharmaceuticals Inc | — | NEW | New buy |
| 21 | OCUL | Ocular Therapeutix Inc | — | NEW | New buy |
| 22 | 260 | Centessa Pharmaceuticals-adr | — | NEW | New buy |
| 23 | ETNBGBP | 89bio Inc | — | NEW | New buy |
| 24 | MNKD | Mannkind CORP | — | NEW | New buy |
| 25 | PCVX | Vaxcyte Inc | — | NEW | New buy |
| 26 | TRML | Tourmaline Bio Inc | — | NEW | New buy |
| 27 | RARE | Ultragenyx Pharmaceutical In | — | NEW | New buy |
| 28 | TSHA | Taysha Gene Therapies Inc | — | NEW | New buy |
| 29 | QURE | uniQure N.V. | — | NEW | New buy |
| 30 | GLUE | Monte Rosa Therapeutics Inc | — | NEW | New buy |
| 31 | AUTL | Autolus Therapeutics PLC | — | NEW | New buy |
| 32 | SEPN | Septerna Inc | — | NEW | New buy |
| 33 | WHWK | Whitehawk Therapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Avoro Capital Advisors LLC reported a total U.S. public equity portfolio value of $11.1B across 33 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including UTHR, ASND, ARGX) accounted for 31.7% of total reported equity market value during Q1 2025.
Top New Position Initiated
UTHR
市值: $824.6M
During Q1 2025, Avoro Capital Advisors LLC's top holdings by market value included UTHR (12.9%)、ASND (12.7%)、ARGX (11.4%). The largest single position, UTHR, represented 12.9% of total portfolio value.
In Q1 2025, Avoro Capital Advisors LLC made 33 total portfolio adjustments, initiating 33 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.